ArticleCureus2025
Monocyte to High-Density Lipoprotein Ratio (MHR) and Monocyte to Lymphocyte Ratio (MLR) in Vitiligo: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Vitiligo is a disorder influenced by oxidative stress and systemic inflammation. While previous studies used difficult-to-perform markers, research on readily available markers like the monocyte to high-density lipoprotein ratio (MHR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), and neutrophil to lymphocyte ratio (NLR) for oxidative stress in vitiligo remains limited, and assessing these markers in stable and unstable vitiligo represents a novel area of research. Materials and methods This case-control study was conducted on 72 vitiligo patients and an equal number of age and gender-matched healthy controls. Out of 72 vitiligo patients, 57 patients had unstable vitiligo and 15 patients had stable vitiligo. Complete blood count (CBC) and fasting lipid profile (FLP) were performed for both cases and controls to assess MHR, MLR, NLR, and PLR. Further, 19 patients on systemic therapy were reassessed after one month. Their ratios were compared before and after treatment. Results Vitiligo patients had significantly higher MHR, MLR, NLR, and PLR as compared to healthy controls. Compared to controls, stable vitiligo patients had no significant difference in these markers. Only PLR was significantly higher in unstable compared to stable vitiligo patients. There was no statistically significant reduction in these markers after one month of systemic treatment in 19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.